Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care.

Oreja-Guevara C, Potra S, Bauer B, Centonze D, Giambastiani MP, Giovannoni G, Kesselring J, Langdon D, Morrow SA, Nouvet-Gire J, Pontaga M, Rieckmann P, Schippling S, Alexandri N, Shanahan J, Thompson H, Van Galen P, Vermersch P, Yeandle D.

Adv Ther. 2019 Sep 5. doi: 10.1007/s12325-019-01071-9. [Epub ahead of print]

PMID:
31487006
2.

How do patients enter the healthcare system after the first onset of multiple sclerosis symptoms? The influence of setting and physician specialty on speed of diagnosis.

Barin L, Kamm CP, Salmen A, Dressel H, Calabrese P, Pot C, Schippling S, Gobbi C, Müller S, Chan A, Rodgers S, Kaufmann M, Ajdacic-Gross V, Steinemann N, Kesselring J, Puhan MA, von Wyl V; Swiss Multiple Sclerosis Registry.

Mult Scler. 2019 Jan 18:1352458518823955. doi: 10.1177/1352458518823955. [Epub ahead of print]

PMID:
31456464
3.

Retinal pathology in experimental optic neuritis is characterized by retrograde degeneration and gliosis.

Manogaran P, Samardzija M, Schad AN, Wicki CA, Walker-Egger C, Rudin M, Grimm C, Schippling S.

Acta Neuropathol Commun. 2019 Jul 17;7(1):116. doi: 10.1186/s40478-019-0768-5.

4.

Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis.

Hayward-Koennecke H, Reindl M, Martin R, Schippling S.

Neurology. 2019 Apr 16;92(16):765-767. doi: 10.1212/WNL.0000000000007312. Epub 2019 Mar 20. No abstract available.

PMID:
30894449
5.

Anatomically constrained tractography facilitates biologically plausible fiber reconstruction of the optic radiation in multiple sclerosis.

Horbruegger M, Loewe K, Kaufmann J, Wagner M, Schippling S, Pawlitzki M, Schoenfeld MA.

Neuroimage Clin. 2019;22:101740. doi: 10.1016/j.nicl.2019.101740. Epub 2019 Mar 1.

6.

[Neurosarcoidosis remains a diagnostic chameleon : First manifestation of neurosarcoidosis as longitudinal transverse myelitis].

Heinen A, Schippling S, Czell D.

Nervenarzt. 2019 Apr;90(4):412-414. doi: 10.1007/s00115-018-0652-8. German. No abstract available.

PMID:
30617568
7.

Optical coherence tomography as a means to characterize visual pathway involvement in multiple sclerosis.

Wicki CA, Hanson JVM, Schippling S.

Curr Opin Neurol. 2018 Oct;31(5):662-668. doi: 10.1097/WCO.0000000000000604. Review.

PMID:
30074495
8.

Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis.

Jelcic I, Hanson JVM, Lukas S, Weber KP, Landau K, Pless M, Reindl M, Weller M, Martin R, Lutterotti A, Schippling S.

J Neuroophthalmol. 2019 Mar;39(1):3-7. doi: 10.1097/WNO.0000000000000669.

PMID:
30015656
9.

Exploring experimental autoimmune optic neuritis using multimodal imaging.

Manogaran P, Walker-Egger C, Samardzija M, Waschkies C, Grimm C, Rudin M, Schippling S.

Neuroimage. 2018 Jul 15;175:327-339. doi: 10.1016/j.neuroimage.2018.04.004. Epub 2018 Apr 6.

PMID:
29627590
10.

Multicenter reliability of semiautomatic retinal layer segmentation using OCT.

Oberwahrenbrock T, Traber GL, Lukas S, Gabilondo I, Nolan R, Songster C, Balk L, Petzold A, Paul F, Villoslada P, Brandt AU, Green AJ, Schippling S.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 13;5(3):e449. doi: 10.1212/NXI.0000000000000449. eCollection 2018 May.

11.

Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL.

Opfer R, Ostwaldt AC, Walker-Egger C, Manogaran P, Sormani MP, De Stefano N, Schippling S.

J Neurol. 2018 May;265(5):1158-1165. doi: 10.1007/s00415-018-8825-8. Epub 2018 Mar 16.

PMID:
29549466
12.

Estimates of age-dependent cutoffs for pathological brain volume loss using SIENA/FSL-a longitudinal brain volumetry study in healthy adults.

Opfer R, Ostwaldt AC, Sormani MP, Gocke C, Walker-Egger C, Manogaran P, De Stefano N, Schippling S.

Neurobiol Aging. 2018 May;65:1-6. doi: 10.1016/j.neurobiolaging.2017.12.024. Epub 2017 Dec 30.

PMID:
29407463
13.

Outer Retinal Dysfunction in the Absence of Structural Abnormalities in Multiple Sclerosis.

Hanson JVM, Hediger M, Manogaran P, Landau K, Hagenbuch N, Schippling S, Gerth-Kahlert C.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):549-560. doi: 10.1167/iovs.17-22821.

PMID:
29372255
14.

Outer Retinal Dysfunction in the Absence of Structural Abnormalities in Multiple Sclerosis.

Hanson JVM, Hediger M, Manogaran P, Landau K, Hagenbuch N, Schippling S, Gerth-Kahlert C.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):549-560.

15.

Safety and preliminary efficacy of deep transcranial magnetic stimulation in MS-related fatigue.

Gaede G, Tiede M, Lorenz I, Brandt AU, Pfueller C, Dörr J, Bellmann-Strobl J, Piper SK, Roth Y, Zangen A, Schippling S, Paul F.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 13;5(1):e423. doi: 10.1212/NXI.0000000000000423. eCollection 2018 Jan.

16.

Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group.

Members of the MS in the 21st Century Steering Group:, Rieckmann P, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Kesselring J, Kobelt G, Langdon D, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P, Aston K, Bauer B, Demory C, Giambastiani MP, Hlavacova J, Nouvet-Gire J, Pepper G, Pontaga M, Rogan E, Rogalski C, van Galen P, Ben-Amor AF.

Mult Scler Relat Disord. 2018 Jan;19:153-160. doi: 10.1016/j.msard.2017.11.013. Epub 2017 Nov 21.

17.

MRI for multiple sclerosis diagnosis and prognosis.

Schippling S.

Neurodegener Dis Manag. 2017 Nov;7(6s):27-29. doi: 10.2217/nmt-2017-0038. No abstract available.

PMID:
29143579
18.

Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.

Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ; ERN-EYE IMSVISUAL.

Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12. Review.

PMID:
28920886
19.

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23.

20.

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.

Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ; CARE-MS I and CAMMS03409 Investigators.

Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 2017 Aug 23. Erratum in: Neurology. 2018 Apr 17;90(16):755.

21.

Diagnostic red flags: steroid-treated malignant CNS lymphoma mimicking autoimmune inflammatory demyelination.

Barrantes-Freer A, Engel AS, Rodríguez-Villagra OA, Winkler A, Bergmann M, Mawrin C, Kuempfel T, Pellkofer H, Metz I, Bleckmann A, Hernández-Durán S, Schippling S, Rushing EJ, Frank S, Glatzel M, Matschke J, Hartmann C, Reifenberger G, Müller W, Schildhaus HU, Brück W, Stadelmann C.

Brain Pathol. 2018 Mar;28(2):225-233. doi: 10.1111/bpa.12496. Epub 2017 Apr 6.

PMID:
28213912
22.

Global and regional annual brain volume loss rates in physiological aging.

Schippling S, Ostwaldt AC, Suppa P, Spies L, Manogaran P, Gocke C, Huppertz HJ, Opfer R.

J Neurol. 2017 Mar;264(3):520-528. doi: 10.1007/s00415-016-8374-y. Epub 2017 Jan 4.

PMID:
28054131
23.

MRI FLAIR lesion segmentation in multiple sclerosis: Does automated segmentation hold up with manual annotation?

Egger C, Opfer R, Wang C, Kepp T, Sormani MP, Spies L, Barnett M, Schippling S.

Neuroimage Clin. 2016 Nov 20;13:264-270. doi: 10.1016/j.nicl.2016.11.020. eCollection 2017.

24.

Optical Coherence Tomography and Magnetic Resonance Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.

Manogaran P, Hanson JV, Olbert ED, Egger C, Wicki C, Gerth-Kahlert C, Landau K, Schippling S.

Int J Mol Sci. 2016 Nov 15;17(11). pii: E1894. Review.

25.

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting.

von Gumberz J, Mahmoudi M, Young K, Schippling S, Martin R, Heesen C, Siemonsen S, Stellmann JP.

PeerJ. 2016 Sep 20;4:e2442. doi: 10.7717/peerj.2442. eCollection 2016.

26.

Restoring immune tolerance in neuromyelitis optica: Part II.

Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Smith TJ, Yeaman MR.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e277. doi: 10.1212/NXI.0000000000000277. eCollection 2016 Oct. Review.

27.

Restoring immune tolerance in neuromyelitis optica: Part I.

Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e276. doi: 10.1212/NXI.0000000000000276. eCollection 2016 Oct. Review.

28.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

29.

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial.

Schippling S, O'Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, Cook S, Filippi M, Hartung HP, Comi G, Jeffery DR, Kappos L, Goodin DS, Arnason B.

J Neurol. 2016 Jul;263(7):1418-26. doi: 10.1007/s00415-016-8146-8. Epub 2016 May 13.

30.

Optical Coherence Tomography in Multiple Sclerosis.

Hanson JV, Lukas SC, Pless M, Schippling S.

Semin Neurol. 2016 Apr;36(2):177-84. doi: 10.1055/s-0036-1582226. Epub 2016 Apr 26. Review.

PMID:
27116724
31.

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium.

Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.

PMID:
27011339
32.

Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant.

Jelcic I, Jelcic I, Kempf C, Largey F, Planas R, Schippling S, Budka H, Sospedra M, Martin R.

Ann Neurol. 2016 Mar;79(3):404-18. doi: 10.1002/ana.24574. Epub 2016 Feb 13.

33.

Atlas based brain volumetry: How to distinguish regional volume changes due to biological or physiological effects from inherent noise of the methodology.

Opfer R, Suppa P, Kepp T, Spies L, Schippling S, Huppertz HJ; Alzheimer's Disease Neuroimaging Initiative.

Magn Reson Imaging. 2016 May;34(4):455-61. doi: 10.1016/j.mri.2015.12.031. Epub 2015 Dec 23.

PMID:
26723849
34.

Optimizing treatment success in multiple sclerosis.

Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, Vollmer T, Schippling S.

J Neurol. 2016 Jun;263(6):1053-65. doi: 10.1007/s00415-015-7986-y. Epub 2015 Dec 24. Review.

35.

JC polyomavirus mutants escape antibody-mediated neutralization.

Ray U, Cinque P, Gerevini S, Longo V, Lazzarin A, Schippling S, Martin R, Buck CB, Pastrana DV.

Sci Transl Med. 2015 Sep 23;7(306):306ra151. doi: 10.1126/scitranslmed.aab1720. Epub 2015 Sep 23.

36.

Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.

Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, Villoslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, de Seze J, Wuerfel JT; Guthy-Jackson Charitable Foundation (GJCF) Neuromyelitis Optica (NMO) International Clinical Consortium and Biorepository, Cabre P, Marignier R, Tedder T, van Pelt D, Broadley S, Chitnis T, Wingerchuk D, Pandit L, Leite MI, Apiwattanakul M, Kleiter I, Prayoonwiwat N, Han M, Hellwig K, van Herle K, John G, Hooper DC, Nakashima I, Sato D, Yeaman MR, Waubant E, Zamvil S, Stüve O, Aktas O, Smith TJ, Jacob A, O'Connor K.

JAMA Neurol. 2015 Jul;72(7):815-22. doi: 10.1001/jamaneurol.2015.0248. Review.

37.

Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group.

Rieckmann P, Boyko A, Centonze D, Elovaara I, Giovannoni G, Havrdová E, Hommes O, Kesselring J, Kobelt G, Langdon D, LeLorier J, Morrow SA, Oreja-Guevara C, Schippling S, Thalheim C, Thompson H, Vermersch P.

Mult Scler Relat Disord. 2015 May;4(3):202-18. doi: 10.1016/j.msard.2015.02.005. Epub 2015 Mar 2. Review.

38.

Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.

Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, Tenembaum S, Banwell B, Greenberg B, Levy M, Fujihara K, Chan KH, Kim HJ, Asgari N, Sato DK, Saiz A, Wuerfel J, Zimmermann H, Green A, Villoslada P, Paul F; GJCF-ICC&BR.

Mult Scler. 2015 May;21(6):678-88. doi: 10.1177/1352458514567216. Epub 2015 Feb 6. Review.

39.

Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.

Sospedra M, Schippling S, Yousef S, Jelcic I, Bofill-Mas S, Planas R, Stellmann JP, Demina V, Cinque P, Garcea R, Croughs T, Girones R, Martin R.

Clin Infect Dis. 2014 Dec 1;59(11):1588-92. doi: 10.1093/cid/ciu682. Epub 2014 Sep 11.

40.

The investigation of acute optic neuritis: a review and proposed protocol.

Petzold A, Wattjes MP, Costello F, Flores-Rivera J, Fraser CL, Fujihara K, Leavitt J, Marignier R, Paul F, Schippling S, Sindic C, Villoslada P, Weinshenker B, Plant GT.

Nat Rev Neurol. 2014 Aug;10(8):447-58. doi: 10.1038/nrneurol.2014.108. Epub 2014 Jul 8. Review. Erratum in: Nat Rev Neurol. 2014 Aug;10(8):i.

PMID:
25002105
41.

Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria.

Schippling S, Balk LJ, Costello F, Albrecht P, Balcer L, Calabresi PA, Frederiksen JL, Frohman E, Green AJ, Klistorner A, Outteryck O, Paul F, Plant GT, Traber G, Vermersch P, Villoslada P, Wolf S, Petzold A.

Mult Scler. 2015 Feb;21(2):163-70. doi: 10.1177/1352458514538110. Epub 2014 Jun 16.

PMID:
24948688
42.

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T; Neuromyelitis Optica Study Group (NEMOS).

J Neurol. 2014 Jan;261(1):1-16. doi: 10.1007/s00415-013-7169-7. Epub 2013 Nov 23. Review.

43.

JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment.

Schippling S, Kempf C, Büchele F, Jelcic I, Bozinov O, Bont A, Linnebank M, Sospedra M, Weller M, Budka H, Martin R.

Ann Neurol. 2013 Oct;74(4):622-6. doi: 10.1002/ana.23973. Epub 2013 Sep 16.

PMID:
23868420
44.

Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis.

Lutterotti A, Yousef S, Sputtek A, Stürner KH, Stellmann JP, Breiden P, Reinhardt S, Schulze C, Bester M, Heesen C, Schippling S, Miller SD, Sospedra M, Martin R.

Sci Transl Med. 2013 Jun 5;5(188):188ra75. doi: 10.1126/scitranslmed.3006168.

45.

Gender differences in circulating levels of neutrophil extracellular traps in serum of multiple sclerosis patients.

Tillack K, Naegele M, Haueis C, Schippling S, Wandinger KP, Martin R, Sospedra M.

J Neuroimmunol. 2013 Aug 15;261(1-2):108-19. doi: 10.1016/j.jneuroim.2013.05.004. Epub 2013 Jun 2.

46.

Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome.

Oberwahrenbrock T, Ringelstein M, Jentschke S, Deuschle K, Klumbies K, Bellmann-Strobl J, Harmel J, Ruprecht K, Schippling S, Hartung HP, Aktas O, Brandt AU, Paul F.

Mult Scler. 2013 Dec;19(14):1887-95. doi: 10.1177/1352458513489757. Epub 2013 May 23.

47.

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort.

Olsson T, Achiron A, Alfredsson L, Berger T, Brassat D, Chan A, Comi G, Eraksoy M, Hegen H, Hillert J, Jensen PE, Moiola L, Myhr KM, Oturai A, Schippling S, Siva A, Sorensen PS, Trampe AK, Weber T, Potts J, Plavina T, Paes D, Subramanyam M, Wiendl H, Dib H, Uren D, Hemmer B, Buck D.

Mult Scler. 2013 Oct;19(11):1533-8. doi: 10.1177/1352458513477925. Epub 2013 Mar 4.

PMID:
23459571
48.

Loss of retinal nerve fibre layer axons indicates white but not grey matter damage in early multiple sclerosis.

Young KL, Brandt AU, Petzold A, Reitz LY, Lintze F, Paul F, Martin R, Schippling S.

Eur J Neurol. 2013 May;20(5):803-11. doi: 10.1111/ene.12070. Epub 2013 Jan 31.

49.

Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.

Stellmann JP, Neuhaus A, Herich L, Schippling S, Roeckel M, Daumer M, Martin R, Heesen C.

PLoS One. 2012;7(11):e50347. doi: 10.1371/journal.pone.0050347. Epub 2012 Nov 29.

50.

Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations.

Zimmermann H, Freing A, Kaufhold F, Gaede G, Bohn E, Bock M, Oberwahrenbrock T, Young KL, Dörr J, Wuerfel JT, Schippling S, Paul F, Brandt AU.

Mult Scler. 2013 Apr;19(4):443-50. doi: 10.1177/1352458512457844. Epub 2012 Aug 30.

PMID:
22936335

Supplemental Content

Loading ...
Support Center